EGFL7 enhances surface expression of integrin α 5 β 1 to promote angiogenesis in malignant brain tumors

Glioblastoma (GBM) is a typically lethal type of brain tumor with a median survival of 15 months postdiagnosis. This negative prognosis prompted the exploration of alternative treatment options. In particular, the reliance of GBM on angiogenesis triggered the development of anti-VEGF (vascular endot...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	EMBO molecular medicine 2018-09, Vol.10 (9)
Hauptverfasser:	Dudvarski Stanković, Nevenka, Bicker, Frank, Keller, Stefanie, Jones, David Tw, Harter, Patrick N, Kienzle, Arne, Gillmann, Clarissa, Arnold, Philipp, Golebiewska, Anna, Keunen, Olivier, Giese, Alf, von Deimling, Andreas, Bäuerle, Tobias, Niclou, Simone P, Mittelbronn, Michel, Ye, Weilan, Pfister, Stefan M, Schmidt, Mirko H
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents, Immunological - administration & dosage Brain Neoplasms - pathology Cell Proliferation Disease Models, Animal Endothelial Cells - metabolism Endothelial Growth Factors - antagonists & inhibitors Endothelial Growth Factors - metabolism Glioblastoma - pathology Heterografts Human Umbilical Vein Endothelial Cells Humans Integrin alpha5beta1 - metabolism Mice Neoplasm Transplantation Neovascularization, Pathologic - physiopathology Survival Analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!